RETRACTED: Lycorine Displays Potent Antitumor Efficacy in Colon Carcinoma by Targeting STAT3
Authors:
Open Access
- 8 August 2018
- journal article
- retracted article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 9, 881
Abstract
Signal transducer and activator of transcription 3 (STAT3) is an attractive therapeutic target for cancer treatment. In this study, we identify lycorine is an effective inhibitor of STAT3, leading to repression of multiple oncogenic processes in colon carcinoma. Lycorine selectively inactivates phospho-STAT3 (Tyr-705), and subsequent molecular docking uncovers that lycorine directly binds to the SH2 domain of STAT3. Consequently, we find that lycorine exhibits anti-proliferative activity and induces cell apoptosis on human colorectal cancer (CRC) in vitro. Lycorine induces the activation of the caspase-dependent mitochondrial apoptotic pathway, as indicated by activation of caspase and increase of the ratio of Bax/Bcl-2 and mitochondrial depolarization. Overexpressing STAT3 greatly blocks these effects by lycorine in CRC cells. Finally, lycorine exhibits a potential therapeutic effect in xenograft colorectal tumors by targeting STAT3 without observed toxicity. Taken together, the present study indicates that lycorine acts as a promising inhibitor of STAT3, which blocks tumorigenesis in colon carcinoma.Keywords
Funding Information
- National Natural Science Foundation of China (81603253, 21711540293, 81673703, 81602614, 81501578)
- Natural Science Foundation of Tianjin Municipality (15JCYBJC54900, 15PTCYSY00030)
This publication has 39 references indexed in Scilit:
- Targeting apoptosis for anticancer therapySeminars in Cancer Biology, 2015
- LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancersNature Communications, 2014
- Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screeningCell Death & Disease, 2014
- The pharmaceutical industry and natural products: historical status and new trendsPhytochemistry Reviews, 2014
- Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitorsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2014
- Cell death and the mitochondria: therapeutic targeting of the BCL‐2 family‐driven pathwayBritish Journal of Pharmacology, 2014
- The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancerBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2014
- Self-consumption: the interplay of autophagy and apoptosisNature Reviews Molecular Cell Biology, 2014
- STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivoInternational Journal of Cancer, 2013
- A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processesBiochemical Pharmacology, 2010